NCT07581379Active, not recruiting
Advancing Precision Lung Cancer Surveillance and Outcomes in Diverse Populations
Protocol for an Observational Cohort Study Integrating Real-World Data and Microsimulation to Assess Imaging Surveillance Strategies in Stage I-IIIA NSCLC Patients in OneFlorida+
Source: ClinicalTrials.gov · Last updated 12 May 2026
Brief summary (registry, in English)
This observational study evaluates the effectiveness of computed tomography (CT) imaging surveillance after curative-intent treatment for stage I-IIIA non-small cell lung cancer (NSCLC) in a diverse U.S. population. The main questions are: How do CT surveillance use and adherence vary by race, ethnicity, and socioeconomic status? Does semi-annual CT surveillance improve outcomes compared with annual surveillance? Adults ages 20-90 with stage I-IIIA NSCLC treated between 2012 and 2026 will be identified using OneFlorida+ electronic health records, tumor registry data, claims, and clinical notes. Patients will be followed for up to five years after curative-intent therapy to evaluate surveillance patterns, recurrence, second primary lung cancers, complications, and survival.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 1826 (actual)
- First submitted
- 1 May 2026
- Start date
- 1 Jan 2012
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- University of Florida
- Diseases
- Lung cancer, Childhood cancers
- NCT number
- NCT07581379
What you commit to
- Study type: Observational
- Participants enrolled: 1826
- From 1 Jan 2012 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- No curative-intent therapy received (e.g., palliative treatment only).
- Patients with recurrence or who die within the first 5 months after starting curative-intent therapy (insufficient window for guideline-defined surveillance).
Other illness
- Histology other than NSCLC, including:
- Small-cell lung cancer Carcinoid tumors Rare non-NSCLC primary tumors
- Metastatic disease (stage IV) at diagnosis.
- Patients with missing identifiers prevent linkage to cancer registries or the death index.
Other
- Patients with incomplete treatment records prevent the determination of the treatment completion date.
- Patients with no surveillance-relevant follow-up data, including:
- No post-treatment clinical notes No radiology/pathology records No linked tumor registry or vital status data
- Individuals whose imaging cannot be classified as surveillance vs. diagnostic due to the absence of relevant structured or unstructured data.
Who the study is looking for
- Adults diagnosed with primary, pathologically confirmed stage I-IIIA non- small cell lung cancer (NSCLC).
- Received curative-intent therapy, including:
- Surgical resection, or Stereotactic body radiation therapy (SBRT), with or without adjuvant therapy.
- Completed curative-intent therapy and survived at least 5 months after therapy initiation.
- Received care within the University of Florida (Gainesville or Jacksonville) health system, and are included in the OneFlorida+ clinical data network.
- Have available:
- Structured EHR data (including tumor registry linkage, imaging, procedures, and vital statistics), and Unstructured clinical documents (clinic notes, radiology reports, pathology reports) enable NLP extraction.
- \- Have ≥1 follow-up encounter in the EHR after treatment completion to allow surveillance assessment.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Florida College of Medicine Coordinator of this site? Confirm its status | Gainesville | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.